On March 22, Heyuan biology was listed on the science and Innovation Board of Shanghai Stock Exchange. In terms of the performance of the secondary market, Heyuan biology made a “good start” on the first day of listing. As of the closing on the 22nd, Heyuan biology reported 21.91 yuan / share, an increase of 65.61%, with a total market value of 10.8 billion yuan.
Jia Guodong, general manager of Heyuan biology, said in an exclusive interview with China Securities Journal that after listing, Heyuan biology will seek further large-scale and global development with the help of capital market forces, consolidate the company’s position in the first echelon of gene therapy cdmo (customized R & D and production organization) with the help of the construction and completion of port industrial base, and repay the majority of investors.
further increase R & D investment
With the sound of gongs, Heyuan biology was officially listed on the science and Innovation Board of Shanghai Stock Exchange, becoming the first share of A-share gene therapy.
Public information shows that Heyuan biology was founded in 2013, focusing on the field of gene therapy, focusing on providing cro services such as gene therapy vector development and gene function research for basic research of gene therapy, as well as cdmo services such as ind-cmc pharmaceutical research and GMP production of clinical samples for research and development of gene drugs.
Listing is the starting point, not the end point. Pan Aodong, chairman of Heyuan biology, said at the listing ceremony that the successful listing indicates that Heyuan biology will take advantage of the capital market to move towards a new development peak. Heyuan biology will continue to focus on the R & D and improvement of gene therapy vectors and the upgrading of industrial production technology, further expand the connotation of the two technology clusters (gene therapy vector development technology, gene therapy vector production process and quality control technology), and strengthen the technical protection system of independent intellectual property rights. At the same time, it will further optimize the business model and improve the ability of international industrial integration.
“R & D is the driving force for the company’s long-term development. In the future, the company will further increase R & D investment and attract global high-end talents.” Jia Guodong told the China Securities Journal that, on the one hand, it will increase investment in basic research, hoping to move towards the “no man’s land” of gene therapy industry and further develop original basic research achievements; On the other hand, we will actively introduce new technologies to rapidly expand production capacity and improve production efficiency, provide customers with better cdmo services and promote the rapid development of gene therapy industry.
industry prospect
Frost Sullivan data show that since 2015, the global gene therapy industry has developed rapidly. From 2016 to 2020, the market scale increased from US $50.4 million to US $2.08 billion; It is estimated that the global gene therapy market will reach US $30.54 billion by 2025.
According to Lin Lijun, managing partner of Shanghai zhengxingu Investment Management Co., Ltd., a shareholder of Heyuan biology, gene and cell therapy industry is an emerging development direction in the medical field. It is expected to maintain rapid growth in the next 20 years and profoundly change the way of human disease treatment, in which cdmo plays a vital role.
Cdmo is mainly an organization that provides pharmaceutical enterprises and biotechnology companies with clinical new drug process development and preparation, as well as listed drug process optimization and large-scale production services, including the production of preclinical and clinical trial drugs and commercial drug production.
Jia Guodong expressed that he is optimistic about the cdmo market of China’s gene therapy industry for a long time, “At present, the development of gene therapy industry is facing the stage of shifting from basic scientific research to industrial application, and the whole industry lacks industrialized talents and technology. Therefore, the gene therapy industry will rely more on the support and promotion of cdmo. At present, China’s gene therapy industry is mainly dominated by start-up biotechnology companies, which have a stronger demand for cdmo because the technology is not enough to speed up the development of new drugs and reduce the risk of R & D.”
“In the field of cdmo, the Chinese enterprises that are catching up with the Chinese heterodyne are shrinking. In the future, Chinese enterprises are more likely to surpass or even lead the development of this field.” Lin Lijun said.
give more patience to enterprises on the science and innovation board
With the listing of Heyuan biology, Kechuang board has officially entered the “400 +” era, and the number of listed companies has reached 401.
Jia Guodong said that the scientific innovation board is a “reform experimental field” for the development of China’s capital market. Since the opening of the market, in the past three years, China Hi-Tech Group Co.Ltd(600730) technology enterprises, especially high-tech start-ups, have accelerated their development with the help of capital market forces.
Lin Lijun believes that the listing of science and Innovation Board will further stimulate the development potential of Heyuan biology in the next stage. With the completion of 77000 square meters near the port and Yuanzhi precision medical industry base in the future, the growth space of Heyuan biology can be expected.
However, the characteristics of high-tech start-ups also determine that they may have inherent business risks such as small business scale, immature products and business models, great uncertainty about the success of innovation and R & D, relatively concentrated customers and low bargaining power of the industrial chain, which may be amplified by changes in the external environment.
“We hope that the majority of investors can give more time for the growth of science and Innovation Board enterprises and be more optimistic about the development of China Hi-Tech Group Co.Ltd(600730) technology enterprises.” Jia Guodong appealed.
Research experts also believe that the market needs to give more patience and peace of mind to accompany and help enterprises grow together for the performance fluctuations caused by the normal operation of science and Innovation Board enterprises in the growth stage.
